{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T09:33:13Z","timestamp":1648805593952},"reference-count":16,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n           Sekund\u00e4re Hypertonie\u20022016 wurden Handlungsempfehlungen zum prim\u00e4ren Hyperaldosteronismus in einer internationalen Leitlinie ver\u00f6ffentlicht, die 2018 speziell aus europ\u00e4ischer Sicht erweitert wurden. Ziel ist es, fr\u00fchzeitig die entsprechenden Patienten zu detektieren, um Endorgansch\u00e4den und kardiovaskul\u00e4ren Ereignissen vorzubeugen. Bei Verdacht auf eine atherosklerotische Nierenarterienstenose eignet sich als Suchtest leitliniengem\u00e4\u00df die farbkodierte Duplexsonografie der Nieren und Nierenarterien. Die Therapie ist in erster Linie medikament\u00f6s.<\/jats:p><jats:p>\n          Obstruktives Schlafapnoe-Syndrom\u2002Protrusionsschienen f\u00fchren zu einem vergleichbaren moderaten Effekt auf den Bluthochdruck wie die bisher etablierte \u00dcberdruckbeatmung. Sie werden von Patienten besser toleriert.<\/jats:p><jats:p>\n          Therapieresistente Hypertonie \u2013 konservative Behandlungsoptionen\u2002Bei der therapieresistenten Hypertonie wird als viertes Medikament Spironolacton empfohlen. Durch die zus\u00e4tzliche Einnahme von Patiromer kommt es insbesondere bei Patienten mit chronischer Nierenerkrankung zu weniger Hyperkali\u00e4mien, wodurch eine sichere Spironolacton-Gabe m\u00f6glich ist.<\/jats:p><jats:p>\n          Therapieresistente Hypertonie \u2013 interventionelle Behandlungsoptionen\u2002Die renale Denervierung kann in den ersten postinterventionellen Monaten zwar zu einer signifikanten Blutdrucksenkung f\u00fchren, die aber deutlich moderater ist als initiale Studien suggerierten.<\/jats:p>","DOI":"10.1055\/a-1262-5777","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T22:34:30Z","timestamp":1622586870000},"page":"742-746","source":"Crossref","is-referenced-by-count":0,"title":["Therapieresistente und sekund\u00e4re Hypertonie"],"prefix":"10.1055","volume":"146","author":[{"given":"Sarah M.","family":"Morell","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, Agaplesion Markus-Krankenhaus, Frankfurt am Main"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar H.","family":"Heine","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II, Agaplesion Markus-Krankenhaus, Frankfurt am Main"},{"name":"Universit\u00e4t des Saarlandes, Saarbr\u00fccken"},{"name":"Kuratorium f\u00fcr Heimdialyse, Neu-Isenburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, Lehrstuhl Endokrinologie und Diabetologie, Universit\u00e4tsklinikum W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association","volume":"72","author":"R M Carey","year":"2018","journal-title":"Hypertension"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice","volume":"69","author":"S Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study","volume":"173","author":"J M Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"S Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"J W Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/EJE-17-0990","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited","volume":"179","author":"T A Williams","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa282","article-title":"Development and Validation of Criteria for Sparing Confirmatory Tests in Diagnosing Primary Aldosteronism","volume":"105","author":"K Wang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"J WM Lenders","year":"2020","journal-title":"J Hypertens"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1001\/jama.2015.16303","article-title":"CPAP vs Mandibular Advancement Devices and Blood Pressure in Patients With Obstructive Sleep Apnea: A Systematic Review and Meta-analysis","volume":"314","author":"D J Bratton","year":"2015","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11325-017-1590-6","article-title":"Effects of CPAP and mandibular advancement device treatment in obstructive sleep apnea patients: a systematic review and meta-analysis","volume":"22","author":"M Schwartz","year":"2018","journal-title":"Sleep Breath"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"B Williams","year":"2015","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"R Agarwal","year":"2019","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"D L Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","article-title":"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial","volume":"390","author":"R R Townsend","year":"2017","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"D E Kandzari","year":"2018","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.jacc.2018.12.082","article-title":"Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension","volume":"73","author":"P Sardar","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1262-5777.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T22:35:51Z","timestamp":1622586951000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1262-5777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":16,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1262-5777","relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}